Pelican Therapeutics, a subsidiary of Heat Biologics, is a pioneering biotech company focused on developing first-in-class therapeutics aimed at achieving in vivo regulatory T cell expansion in humans. The company operates in the biopharmaceutical market, targeting both clinical and research sectors. Pelican Therapeutics primarily serves healthcare providers, research institutions, and pharmaceutical companies looking for advanced immunotherapy solutions. The business model revolves around the development and commercialization of novel T cell costimulators, such as their flagship product PTX-35, which selectively stimulates memory CD8 T cells. Revenue is generated through grants, partnerships, and eventual product sales upon regulatory approval. The company has secured significant funding, including a $15.2 million CPRIT grant, to advance its research and development efforts.

Keywords: immunotherapy, T cell expansion, CD8 T cells, PTX-35, biopharmaceutical, regulatory T cells, clinical research, healthcare providers, biotech, CPRIT grant.